Anemia in cancer patients: Evaluating the risk of treatment-induced anemia and classification of therapies

Home / Anemia in cancer patients: Evaluating the risk of treatment-induced anemia and classification of therapies

Anemia in cancer patients: Evaluating the risk of treatment-induced anemia and classification of therapies

The incidence of anemia in cancer patients is high, and varies depending on the type of treatment the patient received. Chemotherapy-induced anemia is well-known, but chemotherapies has never been classified according to the risk of anemia, as it has been performed for chemotherapy-induced nausea and vomiting (CINV). In addition, Phase 3 studies have also reported anemia with the use of targeted therapies.

The aim of the C-KIN Working Group is to review the available data and build a classification of the risk of treatment-induced anemia, including chemotherapy and targeted therapies.

Members of the Working Group

  • Co-Chair: Florian Scotté – France – Oncology
  • Co-Chair: Vincent Launay-Vacher – France – Clinical Pharmacology
  • Marie-Sarah Dilhuydy – France – Haematogoly
  • Laurent Zelek – France – Oncology
  • Guillaume Cartron – France – Onco-haematology
  • Didier Mayeur –  France –  Oncology
#list-style-5a0fd370db055 ul li:before { font-family:Icomoon; content: "\e094"; color:#1866ad }

For more information about the Working Group, please contact us at info@c-kin.org

Logo-PF Oncologie-FR-Q-4mm-01

The C-KIN WG is supported by a Pierre Fabre grant.

About Pierre Fabre

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2015, it generated over 2.2 billion euros in sales, of which 57% came from the dermo-cosmetics sector, and 58% from international business. Pierre Fabre, which has always been based in the Languedoc-Roussillon-Midi-Pyrénées region in southern France, has subsidiaries in 43 countries and distribution agreements in over 130 countries.

Pierre Fabre Laboratories employs some 13,000 people worldwide. The company’s products represent a continuum ranging from prescription drugs, dermo-cosmetics, to consumer health care (family health care, oral care and natural health). In 2015, the company dedicated almost 200 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics. www.pierre-fabre.com